BRD9 and acute myeloid leukemia: In this report, we found that BRD9 KD, BRD9 inhibition, or BRD9 degradation, which lead to downregulation of MYC in some subtypes of AML and MM,34,35 potentiated the effects of IMiDs, including lenalidomide and pomalidomide, and conversely, IKZF3 or MYC overexpression could partially reverse this synergy.